Continuous Launch of New Products Expanding New Products in Japan Strengthening Our Sales Platform in  Emerging Countries In emerging countries, we are looking to reinforce our  Having developed its own sales network in more than 50  countries around the world, Astellas has a well-balanced  global business spanning the four regions of Japan, the  Americas, EMEA and Asia & Oceania. In addition to global  products, such as mirabegron and XTANDI, we also  market distinctive new products in each region. These  products underpin our growth and constitute one of our  key strengths. in Japan with Amgen Inc. to expand our product  portfolio. Under this alliance, we will co-develop and  co-commercialize five of Amgen’s pipeline medicines  through our Tokyo-based joint venture, Amgen Astellas  BioPharma KK. sales platform, notably in China and Russia. We expect  emerging markets to continue growing, but governments  in these countries are implementing measures to curb  healthcare spending at an even faster rate than developed  countries. National and regional market characteristics  also vary greatly. Astellas has one of Japan’s top sales/marketing platforms,  with a sales force of around 2,400 medical representatives  (MRs). Our strong presence supports a broad portfolio that  contains numerous growth drivers and new products.  In 2014, we launched Suglat as Japan’s first SGLT2  inhibitor for the treatment of type 2 diabetes in April, fol- lowed by XTANDI in May. Both of these new products will  support our future growth in Japan as we work to steadily  increase their market penetration.  In May 2013, we entered into a strategic alliance  * Other: Total sales of affiliates located in emerging pharmaceutical markets  as defined by IMS Health Incorporated, excluding China and Russia.  (Brazil, India, Turkey, Thailand, Vietnam, Indonesia, Poland, Romania,  South Africa) * New product group: Total sales of products launched within the past three  years. (ARGAMATE, Kiklin, Regnite, Gonax, Cimzia, Acofide) Annual Report 2014 _  Astellas Pharma Inc.  25 Business Strategy While taking the characteristics and changes in busi- ness conditions in these emerging markets into account,  our strategy is to focus on high-value-added new drugs,  just as in advanced economies. Our policy is to develop  operations steadily to help generate reliable future   earnings streams. Sales in Emerging Markets (¥ billion) J-GAAp Approx. ¥96.0 (+36% YoY) Excluding forex impact +11% YoY Other* China Russia Approx. ¥71.0 100 50 75 25 0 +13%  (Local currency basis) +12%  (Local currency basis) 2013.3 2014.3 Sales of Growth Drivers and new products in Japan  (Excluding Global products) (¥ billion) J-GAAp 95.7 120.0 (+25% YoY) 7.6 14.2 35.6 27.7 14.1 12.3 10.7 11.7 37.4 44.3 120 80 40 0 2014.3 2013.3 New product  group* (+87%) Symbicort (+29%) Bonoteo (+32%) Geninax (–5%) Celecox (+18%)